Literature DB >> 17544313

[Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].

N Roger1, I Popovic, P Madelenat, D Mahieu-Caputo.   

Abstract

The fetal toxicity of angiotensin-converting enzyme inhibitors (ACEI) is now well known. Sartans which are angiotensin II inhibitors, are supposed to have the same side effects on the fetus as ACEI because of their similar mechanism of action. This is supported by experimental and clinical data. Clinical presentation of fetal exposition to sartans varies from transient oligamnios to permanent renal failure, potentially complicated by Potter syndrome. According to previously reported cases, we report a case of transitory fetal oliguria secondary to the exposure to an angiotensin-II-receptor inhibitor (valsartan) between 19 and 21 weeks' gestation. We discuss the management of pregnancies exposed to angiotensin II inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544313     DOI: 10.1016/j.gyobfe.2007.03.015

Source DB:  PubMed          Journal:  Gynecol Obstet Fertil        ISSN: 1297-9589


  2 in total

Review 1.  Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review.

Authors:  Chisa Shimada; Rina Akaishi; Kazutoshi Cho; Mamoru Morikawa; Yosuke Kaneshi; Takahiro Yamda; Hisanori Minakami
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

2.  RAS in Pregnancy and Preeclampsia and Eclampsia.

Authors:  M Rodriguez; J Moreno; J Hasbun
Journal:  Int J Hypertens       Date:  2012-12-30       Impact factor: 2.420

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.